Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

This phase II trial was designed to evaluate the benefit of daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma. The 24-month progression-free survival rate ranged from 75.3% to 89.9%, depending on dosing intensity.

Phase III trials to evaluate daratumumab monotherapy in smoldering multiple myeloma are warranted.


Spread the word. Share this post!